The Checkmate-227 trial enrolled treatment-naïve metastatic NSCLC patients to receive a standard platinum-based chemotherapy, a combination of nivolumab and ipilimumab, or nivolumab as a single agent if PD-L1 ≥1% or associated with chemotherapy if PD-L1 negative (26). The gene discussed is CD274; the disease is non-small cell lung carcinoma.